	US 12,415,832 B2
	B-catenin/B-cell Lymphoma 9 protein-protein interaction inhibiting peptidomimetics
Jianfeng Cai, Tampa, FL (US); Peng Sang, Tampa, FL (US); Yan Shi, Tampa, FL (US); Haitao Ji, Tampa, FL (US); and Min Zhang, Tampa, FL (US)
Assigned to UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US); and H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC., Tampa, FL (US)
Appl. No. 17/605,219
Filed by University of South Florida, Tampa, FL (US); and H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC., Tampa, FL (US)
PCT Filed Apr. 24, 2020, PCT No. PCT/US2020/029730 § 371(c)(1), (2) Date Oct. 20, 2021, PCT Pub. No. WO2020/219819, PCT Pub. Date Oct. 29, 2020.
Claims priority of provisional application 62/837,911, filed on Apr. 24, 2019.
Prior Publication US 2022/0220153 A1, Jul. 14, 2022
Int. Cl. C07K 7/02 (2006.01); A61K 38/08 (2019.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 7/02 (2013.01) [A61K 38/08 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 38/00 (2013.01)]

13 Claims

1. A sulfono-γ-AApeptide compound having the structure of Formula I:

wherein G₁is hydrogen, acetyl group, linker group, or a blocking group;

wherein R₁is a hydrogen or C₁-C₆alkyl;

wherein each of R₂, R₄, and R₃₀is independently hydrogen, C1-C6 alkyl, or a group having a structure with the formula:

wherein m is an integer having a value of 0, 1, 2, 3, 4, 5, or 6;

wherein each of R₃, R₅, and R₆is independently hydrogen, C1-C6 alkyl, or C1-C6 hydroxyalkyl;

wherein each of R₇, R₁₀, and R₁₂is independently hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or C1-C6 aminoalkyl;

wherein each of R₈, R₉, R₁₁, R₁₃, and R₁₄is independently hydrogen or C1-C6 alkyl;

wherein R₁₅is hydrogen, C1-C6 alkyl, aryl, or heteroaryl;

wherein R₂₀is hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, -(C1-C6 alkanediyl)-(C═O) OH, or, -(C1-C6 alkanediyl)-(C═O) NH₂; and

wherein each of R₄₀, R₄₁, and R₄₂is independently is independently a C1-C6 alkyl;

or a pharmaceutically acceptable salt thereof.